Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (-)-epigallocatechin 3-gallate | multiple interactions | EXP | | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF485 mRNA | CTD | PMID:22079256 | 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of ZNF485 mRNA | CTD | PMID:31614463 and PMID:36828454 | aflatoxin B1 | increases expression | EXP | | 6480464 | Aflatoxin B1 results in increased expression of ZNF485 mRNA | CTD | PMID:22100608 | Aflatoxin B2 alpha | increases methylation | EXP | | 6480464 | aflatoxin B2 results in increased methylation of ZNF485 exon | CTD | PMID:30157460 | antirheumatic drug | increases expression | EXP | | 6480464 | Antirheumatic Agents results in increased expression of ZNF485 mRNA | CTD | PMID:24449571 | aristolochic acid A | decreases expression | EXP | | 6480464 | aristolochic acid I results in decreased expression of ZNF485 mRNA | CTD | PMID:33212167 | benzo[a]pyrene | increases methylation | EXP | | 6480464 | Benzo(a)pyrene results in increased methylation of ZNF485 exon | CTD | PMID:27901495 | benzo[a]pyrene | affects methylation | EXP | | 6480464 | Benzo(a)pyrene affects the methylation of ZNF485 exon and Benzo(a)pyrene affects the methylation of ZNF485 promoter | CTD | PMID:27901495 and PMID:30157460 | benzo[e]pyrene | increases methylation | EXP | | 6480464 | benzo(e)pyrene results in increased methylation of ZNF485 exon | CTD | PMID:30157460 | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of ZNF485 mRNA | CTD | PMID:36828454 | copper(II) sulfate | decreases expression | EXP | | 6480464 | Copper Sulfate results in decreased expression of ZNF485 mRNA | CTD | PMID:19549813 | dioxygen | decreases expression | EXP | | 6480464 | Oxygen deficiency results in decreased expression of ZNF485 mRNA | CTD | PMID:26516004 | dorsomorphin | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF485 mRNA | CTD | PMID:27188386 | formaldehyde | decreases expression | EXP | | 6480464 | Formaldehyde results in decreased expression of ZNF485 mRNA | CTD | PMID:20655997 | methapyrilene | increases methylation | EXP | | 6480464 | Methapyrilene results in increased methylation of ZNF485 exon | CTD | PMID:30157460 | nickel sulfate | decreases expression | EXP | | 6480464 | nickel sulfate results in decreased expression of ZNF485 mRNA | CTD | PMID:22714537 | potassium chromate | decreases expression | EXP | | 6480464 | potassium chromate(VI) results in decreased expression of ZNF485 mRNA | CTD | PMID:22079256 | potassium chromate | multiple interactions | EXP | | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF485 mRNA | CTD | PMID:22079256 | SB 431542 | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF485 mRNA | CTD | PMID:27188386 | silicon dioxide | increases expression | EXP | | 6480464 | Silicon Dioxide analog results in increased expression of ZNF485 mRNA | CTD | PMID:25895662 | sodium arsenite | decreases expression | EXP | | 6480464 | sodium arsenite results in decreased expression of ZNF485 mRNA | CTD | PMID:22714537 | sunitinib | decreases expression | EXP | | 6480464 | Sunitinib results in decreased expression of ZNF485 mRNA | CTD | PMID:31533062 | temozolomide | increases expression | EXP | | 6480464 | Temozolomide results in increased expression of ZNF485 mRNA | CTD | PMID:31758290 | urethane | decreases expression | EXP | | 6480464 | Urethane results in decreased expression of ZNF485 mRNA | CTD | PMID:28818685 | vorinostat | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF485 mRNA | CTD | PMID:27188386 | zearalenone | increases expression | EXP | | 6480464 | Zearalenone results in increased expression of ZNF485 mRNA | CTD | PMID:36828454 | zoledronic acid | decreases expression | EXP | | 6480464 | zoledronic acid results in decreased expression of ZNF485 mRNA | CTD | PMID:20977926 | |